Paper32905214
Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature.
Song L and 2 others. Mol Clin Oncol, 2020. Cited by 11 papers, by iCite.
Cite this record
ConductScience Library. Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature. Papers, record 32905214. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32905214
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Combination nivolumab and bevacizumab for metastatic myxofibrosarcoma: A case report and review of the literature.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References14
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 28988646 | Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28988646 | PubMed |
| 2 | 29370992 | Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/29370992 | PubMed |
| 3 | 30591101 | [First-line Combination Immunotherapy in Advanced Non-small Cell Lung Cancer]. | Zhongguo Fei Ai Za Zhi | 2018 | https://conductscience.org/library/papers/30591101 | PubMed |
| 4 | 19451427 | Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). | J Clin Oncol | 2009 | https://conductscience.org/library/papers/19451427 | PubMed |
| 5 | 28440953 | Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: Results of a phase 2 study. | Cancer | 2017 | https://conductscience.org/library/papers/28440953 | PubMed |
| 6 | 22595799 | Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. | Lancet | 2012 | https://conductscience.org/library/papers/22595799 | PubMed |
| 7 | 27087380 | [Chinese expert consensus on diagnosis and treatment of soft tissue sarcomas (Version 2015)]. | Zhonghua Zhong Liu Za Zhi | 2016 | https://conductscience.org/library/papers/27087380 | PubMed |
| 8 | 26167500 | Immunotherapy for Bone and Soft Tissue Sarcomas. | Biomed Res Int | 2015 | https://conductscience.org/library/papers/26167500 | PubMed |
| 9 | 16192597 | Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. | J Clin Oncol | 2005 | https://conductscience.org/library/papers/16192597 | PubMed |
| 10 | 15396 | Myxofibrosarcoma. A study of 30 cases. | Acta Pathol Microbiol Scand A | 1977 | https://conductscience.org/library/papers/15396 | PubMed |
| 11 | 28042471 | Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. | Clin Sarcoma Res | 2016 | https://conductscience.org/library/papers/28042471 | PubMed |
| 12 | 28794805 | Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations. | Ther Adv Med Oncol | 2017 | https://conductscience.org/library/papers/28794805 | PubMed |
| 13 | 30253794 | Response to PD1 inhibition in conventional chondrosarcoma. | J Immunother Cancer | 2018 | https://conductscience.org/library/papers/30253794 | PubMed |
| 14 | 29895706 | Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma. | Clin Cancer Res | 2018 | https://conductscience.org/library/papers/29895706 | PubMed |
Cited by8
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 11 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41718124 | Single-Cell RNA Sequencing Reveals the Cellular and Molecular Differences Between Myxofibrosarcoma and Undifferentiated Pleomorphic Sarcoma. | Med Sci (Basel) | 2026 | https://conductscience.org/library/papers/41718124 | PubMed |
| 38928713 | Giant Myxofibrosarcoma in the Lower Limb: An Overview of Diagnostic and Clinical Management. | Diagnostics (Basel) | 2024 | https://conductscience.org/library/papers/38928713 | PubMed |
| 37958307 | Modeling Myxofibrosarcoma: Where Do We Stand and What Is Missing? | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37958307 | PubMed |
| 37835765 | Biology and Management of High-Grade Myxofibrosarcoma: State of the Art and Future Perspectives. | Diagnostics (Basel) | 2023 | https://conductscience.org/library/papers/37835765 | PubMed |
| 35782752 | Myxofibrosarcoma landscape: diagnostic pitfalls, clinical management and future perspectives. | Ther Adv Med Oncol | 2022 | https://conductscience.org/library/papers/35782752 | PubMed |
| 34269922 | Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors. | Curr Oncol Rep | 2021 | https://conductscience.org/library/papers/34269922 | PubMed |
| 33594507 | [Subcutaneous nodule on the lower leg of an 87-year-old man]. | Hautarzt | 2021 | https://conductscience.org/library/papers/33594507 | PubMed |
| 33562486 | Gemcitabine-Containing Chemotherapy for the Treatment of Metastatic Myxofibrosarcoma Refractory to Doxorubicin: A Case Series. | Curr Oncol | 2021 | https://conductscience.org/library/papers/33562486 | PubMed |
Genes15
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32905214
GET https://conductscience.org/api/papers/v1/32905214/authors